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Abstract
Indonesia is the 2nd country with the highest tuberculosis (TB) caseload in the world. Inappropriate TB treatment 
may lead to multidrug-resistance tuberculosis (MDR-TB) development. Tuberculosis rapid detection is important, 
and very much needed, to prevent transmission and deaths due to this disease. The Xpert® MTB/RIF is proposed 
to address this problem. This study aimed to assess the performance of the Xpert® MTB/RIF test in West Java, 
Indonesia. This was a cross-sectional study conducted on MDR-TB suspects referred to Dr. Hasan Sadikin General 
Hospital Bandung, West Java, Indonesia, using data from the eTB Manager. The performance of Xpert® MTB/RIF 
testing and its validity was tested against conventional drug susceptibility testing (DST). In total, data from 4,452 
MDR-TB suspects were retrieved but only 578 data that had both DST and Xpert® MTB/RIF results were included 
in the study. The Xpert® MTB/RIF showed a sensitivity of 88% (95%CI: 85%-91%), specificity of 66% (95%CI: 
60%-72%), positive predictive value of 79% (95%CI: 75%-83%), and negative predictive value of 80% (95%CI: 
74%-85%), with a detection accuracy of 79%. Xpert® MTB/RIF test in this study shows a good performance 
for the diagnosis of MDR-TB when compared to the Mycobacterium tuberculosis culture as the gold standard. 
Therefore, rapid Xpert® MTB/RIF examination is recommended for MDR-TB screening for countries with a high 
TB burden as a complementary tool to the reference standard test.
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Performa Xpert® MTB/RIF Dalam Mendeteksi Tuberculosis Resisten Obat 
di Jawa Barat, Indonesia 
Abstrak 
Indonesia adalah negara urutan ke-2 dengan jumlah kasus tuberkulosis (TB) tertinggi di dunia. Pengobatan TB 
yang tidak sesuai dapat mengakibatkan kuman TB menjadi resisten terhadap obat TB yang disebut TB multidrug-
resistances (TB-MDR). Untuk itu diperlukan alat deteksi yang mumpuni sehingga kuman TB-DR dapat segera 
didiagnosis dan diberikan pengobatan yang tepat; dengan demikian pencegahan dan kematian akibat TB dapat 
ditekan. Penelitian ini bertujuan mengukur performa mesin Xpert® MTB/RIF dalam mendeteksi kuman TB-MDR 
di Jawa Barat, Indonesia. Studi potong lintang dilakukan dengan mengambil data dari 4452 pasien terduga TB-
MDR yang terregistrasi di eTB Manager selama tahun 2012–2016 yang dikirim ke Rumah Sakit Dr. Hasan Sadikin 
Bandung. Walaupun demikian, hanya 578 yang memiliki hasil test kultur untuk mengetahui sensitivitas obat TB. 
Dari kedua test tersebut, didapatkan Xpert® MTB/RIF memiliki sensitivitas 88% (95% IK: 85%–91%), spesifisitas 
66% (95% IK: 60%–72%), positive predictive value 79% (95% IK: 75%-83%), dan negative predictive value 80% 
(95% IK: 74%-85%), dengan akurasi 79%. Test TB-MDR menggunakan Xpert® MTB/RIF pada penelitian ini 
menunjukkan performa yang baik sehingga test ini sangat direkomendasikan untuk deteksi TB-MDR yang cepat, 
utamanya di daerah dengan prevalensi TB yang tinggi. 
Kata kunci: MDR-TB, Sensitivitas, Spesifisitas, Xpert® MTB/RIF
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Introduction
Based on the Global Tuberculosis Report 2019, 
Indonesia is categorized as a country with the 
second-highest burden of tuberculosis (TB) in 
the world.1 The National Health Research Data 
has reported that West Java is the province 
with the highest TB prevalence in Indonesia;2 
however, only 56.2% of TB patients have been 
treated with anti-TB drugs, including isoniazid 
(INH), rifampicin (RIF), pyrazinamide (PZA), 
ethambutol (EMB), and streptomycin (STR) 
that are given as a directly observed treatment 
short-course (DOTS) program in two treatment phases.3
It is a well-known fact that inappropriate 
TB treatment may lead to multidrug-resistance 
tuberculosis (MDR-TB) due to the failure 
elimination of the bacteria, leading to resistant or mutant development.4 The mutant bacteria acquire resistance that is transmitted into other hosts via air-droplet nuclei and further infect 
the new host with primary resistance.5 MDR-TB 
is defined as resistance to at least two anti-TB 
drugs, especially INH and RIF. Around 12% of 
the new MDR-TB cases in Indonesia are caused 
by inappropriate TB treatment.1 Because MDR-
TB has a high mortality rate, rapid diagnosis is needed to reduce transmission and to increase the treatment success rate.6
Various methods have been applied for 
MDR-TB detection including, among others, conventional culture methods, phenotype 
methods, and genotype molecular methods. The 
egg-based culture media (Lowenstein-Jensen 
media) with drug susceptibility test (DST) is 
used as a gold standard for TB detection, but 
this method needs 8–12 weeks for completing 
the diagnosis. To deal with the challenge of the 
slow detection time of the conventional method, 
a new method referred to as the Xpert® MTB/
RIF (Cepheid, USA) has been introduced in 2004. 
This method applies the real-time polymerase 
chain reaction (RT-PCR) technics and is endorsed 
by the WHO in 2010.7
Indonesia has implemented the rapid Xpert® 
MTB/RIF detection by joining the TBXpert 
project. However, data on the Xpert® MTB/
RIF detection validity as the new gold standard to complement the conventional method are 
limited. Therefore, this study aimed to describe 
the performance and validity of Xpert® MTB/
RIF in detecting MDR-TB cases in Indonesia as 
one of the countries with a high TB burden.
Methods
This was a comparative cross-sectional study on 
TB diagnostic testing using the Xpert® MTB/
RIF (Cepheid, USA) as the index test with the 
DST culture as the reference test result. This 
study was conducted in 2017 by reviewing the 
performance of Xpert® MTB/RIF compared to a conventional method for drug-sensitive test 
(DST). Data from suspected MDR-TB patients 
registered in the eTB Manager database from 
May 2012 until December 2016 were analyzed 
for their sensitivity, specificity, false-positive, false-negative, and accuracy values.
In brief, suspected MDR-TB patients from 
various districts and cities throughout West 
Java Province were referred to Dr. Hasan Sadikin 
General Hospital Bandung (Figure), in order to 
confirm the MDR-TB diagnosis, using Xpert® 
MTB/RIF. Of note, the year 2012 was the first 
time that Xpert® MTB/RIF was installed in this 
province. Data of suspected MDR-TB patients 
registered in eTB was collected, including age, 
Ziehl-Neelsen (ZN) smear result or otherwise 
fulfilled the definition of risk category of 
MDR-TB patients by National Guideline for 
Tuberculosis, Ministry of Health Republic of 
Indonesia as depicted in Table 1.3 Only data of 
suspected MDR-TB patients with complete valid 
both DST culture and Xpert® MTB/RIF result 
was included in the analysis. The study protocol 
was permitted by the Ethical Committee of Dr. Hasan Sadikin General Hospital Bandung and the Faculty of Medicine, Universitas Padjadjaran 
under registration number of 0117030289 and 
713/UN6.C.10/PN/2017, respectively. 
Suspected MDR patients were defined 
according to the Definition of Risk Category of 
MDR-TB patients in the National Guideline for 
Tuberculosis, Ministry of Health Republic of 
Indonesia, as presented in Table 1.3 Patients were 
asked to collect two consecutive expectorated 
morning sputum samples within the same day 
to be sent to the hospital. In brief, a minimum 
of 1mL sputum sample was collected in sterile 
tubes and stored at 2–8oC for a maximum of 3 
days. The sample was then divided for three 
purposes: ZN smear microscopic examination, 
culture using DST method, and Xpert® MTB/RIF 
examination.
Smear grading was performed according to the 
WHO/International Union Against Tuberculosis 
and Lung Disease. DST culture was performed 
at the Clinical Microbiology Laboratory of Balai 
Laboratorium Kesehatan, Bandung, whereas the 
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Table 1 Definition of Risk Category of MDR-TB Patients According to the National Guideline for 
 Tuberculosis, Ministry of Health of the Republic of Indonesia3
Risk Category Definition
Chronic TB patient Patients who are still sputum smear-positive at the end 
of the first-line TB re-treatment (Category 2)
TB patient with 2nd category treatment which not converted in 3 months of treatment Patients on first-line TB re-treatment (Category 2) who are tested as smear-positive after 3 months of treatment
TB patient who have a non-standard TB treatment history using quinolone and 2nd line anti-
tuberculosis drug injection for at least 1 month
Patients who received any type of TB treatment 
outside of the national program (example: non-DOTS, 
private clinic)
TB patients who failed 1st category treatment Patients who are still sputum smear-positive at the end 
of the first-line TB treatment (Category 1)
TB patients with 1st category treatment who remain positive after 3 months of  treatment Patients on first-line TB treatment (Category 1) who are tested as smear-positive after 3 months of treatment
Relapse TB patient, categories 1 and 2 Patients whose most recent treatment outcome 
(Category 1 or 2) was ‘cured’ or ‘treatment completed’ 
and return with symptoms of TB
Returning TB patients after loss to follow-up 
(negligent treatment/default)
Patients who interrupted any type of TB treatment 
for 2 or more consecutive months and return with 
symptoms of TB
Suspected TB patients with a history of close contact 
with MDR-TB patients
People living in the same household or spending many 
hours a day in the same indoor living space with an 
MDR-TB patient and who show symptoms of TB
TB-HIV co-infection patients who do not respond to 
anti-tuberculosis drug administration
Patients who are tested positive for HIV and TB with diagnostic tests
Xpert® MTB/RIF examination was conducted 
at the Clinical Pathology Laboratory, Dr. Hasan 
Sadikin General Hospital Bandung. Patients’ 
sputum samples were taken to the Laboratory 
and the DST culture was carried out on 
Lowenstein-Jensen (LJ) media. The result was 
expected to be received after 8–12 weeks.
The patient’s sputum sample was taken to the 
Xpert® MTB/RIF laboratory and then thawed 
and inactivated by adding a sterilizing agent 
containing NaOH and isopropanol at the ratio 
of 2:1, followed by incubation for 15 minutes at 
room temperature. Two milliliters of samples 
were then transferred into the Xpert® MTB/RIF 
cartridge. The cartridge was then loaded into the 
Xpert® MTB/RIF instrument and the result was 
generated after 2 hours. Results were reported as 
MTB positive or negative, with semi-quantified 
bacillary load categorized as high, medium, low, 
or very low. Results were also categorized into 
RIF-resistant MTB and RIF-susceptible MTB. The 
diagnostic tests were conducted by laboratory 
technicians supervised by a clinical pathologist 
with experiences in running TB diagnostic tests. 
Patient data and the laboratory results 
were presented in frequency and tables. The 
sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV) of DST, 
and Xpert® MTB/RIF accuracy-test were then 
calculated statistically (SPSS version 22; IBM 
Inc.)
Results
Between May 2012 and December 2016, there 
were 4,452 suspected MDR-TB patients referred 
from various places in West Java Province to 
Dr. Hasan Sadikin General Hospital, which is 
located in Bandung, the capital city of West Java 
Province (Figure), consisting of 54.7% male and 
45.3% female TB patients with a median age of 
43 (range 1–94) and 39 (range 1–90) years old, 
respectively with most of them (80.1%) were in 
the productive years (Table 2). HIV examination 
was not performed in most TB patients. Only 448 
patients (10%) were tested for HIV and 8 (1.8%) 
were positive.
After the dissemination of the Xpert® MTB/
RIF examination program in West Java, the 
E Sahiratmadja, et al: Performance of Xpert® MTB/RIF in Detecting Multidrug-Resistance Tuberculosis in West Java, Indonesia
Majalah Kedokteran Bandung, Volume 52 No. 2, June 2020102
Table 2 Age distribution among all MDR-TB patients referred for Xpert® MTB/RIF 
  Examination in Dr. Hasan Sadikin General Hospital, Bandung, West Java – Indonesia,  
  2012–2016  
Male Female Total
n n n (%)
Age<10 27 43 70 (1.6%)
11–20 99 177 276 (6.2%)
*21–30 404 382 786 (17.7%)
*31–40 537 487 1024 (23%)
*41–50 497 410 907 (20.4%)
*51–60 534 313 847 (19%)
61–70 226 142 368 (8.3%)
>70 111 63 174 (3.9)
Total 2435 2017 4452 (100%)
Note: productive years were defined as between 21–60 years old
Table 3 Distribution of Xpert® MTB/RIF Examination and its Results in 2012–2016 for 
 All MDR TB patients referred to Dr. Hasan Sadikin General Hospital, Bandung, West 
 Java–Indonesia
Xpert® MTB/RIF Positive Negative Indeterminate
n (%) n (%) n (%) n (%)
Total 4452 (100) 2085 (46.8) 2126 (47.8) 241 (5.4)Year2012 55 (1.2) 37 (67.3) 3 152013 530 (11.9) 269 (50.7) 225 36
2014 910 (20.4) 387 (42.5) 476 472015 1544 (34.7) 745 48.2) 740 59
2016 1413 (31.7) 647 (45.7) 682 84
Suspected MDR-TB Criteria†1 303 (6.8) 195 91 172 213 (4.8) 152 51 103 45 (1.0) 30 11 4
4 547 (12.3) 297 215 355 563 (12.6) 399 140 24
*6 1994 (44.8) 653 1233 108
7 649 (14.6) 338 282 29
8 100 (2.2) 11 81 8
9 38 (0.9) 10 22 6
Note: * the most criterion of suspected MDR TB patients referred for Xpert® MTB/RIF examination. †Suspected MDR-
TB Criteria according to the Ministry of Health of the Republic of Indonesia
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number of suspected MDR-TB patients referred 
to the hospital increased (Table 3); however, the 
result of Xpert® MTB/RIF examination revealed 
positive results in only 2,085 (46.8%) suspected 
MDR-TB patients (Table 3). Interestingly, most of the criteria used for referring patients to 
the hospital were in category 6, designated as 
relapsed TB patients (categories 1 and 2). These 
patients had been declared as being cured or had 
completed treatment; however, they returned 
to the primary health care with symptoms of 
TB. Interestingly, of those patients in category 
Table 4 Distribution of Drug Sensitivity Test 
 among MDR-TB patients referred   
 to Dr. Hasan Sadikin General 
 Hospital Bandung, West Java,    
 Indonesia in 2012–2016 
Result n (%)n=578Positive
Monoresistance RIF 36 (6.2)Monoresistance INH 46 (8.0)
MDR-TB 339 (58.7)Negative 157 (27.2)
6 (n=1,994), only (32.7%) (653 of 1,994) had a 
positive result on Xpert® MTB/RIF examination.
After retrieving data on both DST and Xpert® 
MTB/RIF examination, only 578 patients data 
were analyzed and further assessed for its 
validity. As for the DST result, only a few had 
monoresistance to INH or RIF with a predominant 
double-resistance to RIF and INH (58.7%, 
n=339) as shown in Table 4. As for the Xpert® 
MTB/RIF results, 65.6% (n =379) were detected 
to have RIF-resistant MTB. The distribution 
of Xpert® MTB/RIF and DST results among 
MDR-TB patients are presented in Table 5. The 
sensitivity and specificity of Xpert® MTB/RIF 
to detect MDR-TB were 88% (95% CI, 85-91%) 
and 66% (95% CI, 60%-72%), respectively, with 
positive and negative predictive values of 79% 
(95% CI, 75%-83%) and 80% (95% CI, 74%-
85%), respectively. The accuracy of Xpert® 
MTB/RIF to detect MDR-TB was 79% (Table 5).
Discussion
 Rapid and accurate diagnosis of pulmonary TB 
remains a big challenge in a country with a high 
burden of TB,  including in Indonesia as a country 
that experiences an increase of prevalence. In 
Figure Distribution of MDR TB Patients from Various Regions in West Java, Indonesia
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2015, Indonesia was ranked 2nd among countries 
with the highest prevalence for TB, after 
previously ranked 5th among countries with the 
highest TB burden.1 This study is a follow-up study 
assessing the performance of the Xpert® MTB/
RIF examination with a larger sample size and 
a longer period.  The first study was conducted 
for two years to explore the performance of the 
Xpert® MTB/RIF machines after the installation 
in West Java. The introduction of this machine 
has increased referral for patients who fail on 
second-line treatment, as well as to initiate 
earlier TB treatment because the conventional 
culture and DST require a longer time for diagnosis.8 Furthermore, the performance of the 
Xpert® MTB/RIF examination has been proven to increase the diagnostic value in  HIV patients.9
Some T patients in this study experienced 
relapse due to possible ineffectiveness of Tb 
detection (n=173; 29.9%). This ineffectiveness 
may lead to TB therapy failure and resistant MTB development.10 Furthermore, the false-negative 
result in the Xpert® MTB/RIF examination in 
this study (6%) is probably due to mutation in 
MTB that might occur in more than 5% of MTB outside the rpoB gene hotspot.11 Further study 
is needed to confirm the possible mutations in 
resistant MTB. Interestingly, there are some 
false-positive results, which accounted for 
almost 15%, and this phenomenon might be due 
to delayed attachment of probes to the bacterial 
DNA site.11 Another possibility is that this might 
be due to the detection of genotypic mutation of rpoB gene MTB strain as RIF resistant but 
phenotypically has not been detected. The mutation on the rpoB gene hotspot at a bacterial 
DNA site is detected using probes.11 This rpoB 
gene, which generates RIF-resistant isolates, 
plays the role of a surrogate marker for MDR-
TB because almost 90% of RIF-resistant isolates 
also exhibit resistance to INH.12
A metanalysis study has clearly shown 
that the Xpert® MTB/RIF has a relatively high sensitivity.13 The machine may be a good 
diagnostic tool for ruling out TB disease in a large 
number of patients due to its high sensitivity 
(95.7%).14 Moreover, 100% sensitivity has been 
shown in a study on both pulmonary and extra-pulmonary samples.15 Such a rule-out sensitivity 
strategy enables primary care doctors to exclude a large proportion of patients suspected as 
suffering from MDR-TB, thereby reducing cost 
and patient burden, as well as speeding up treatment initiation.  
In terms of the specificity of Xpert® MTB/
RIF, this present study suggested a relatively low 
specificity compared to the specificity identified 
in a study in 5 countries, i.e. Peru, Azerbaijan, 
South Africa, and India, with a specificity that 
ranges from 97.1% to 100%. However, results 
from Tanzania presented a lower specificity 
than the one in this study for Xpert® MTB/
RIF.16 Therefore, the use of Xpert® MTB/RIF 
as a biomarker for monitoring TB treatment is 
crucial but should not replace the conventional 
method in ruling out TB or MDR-TB. For example, 
a study in Indonesia has shown a high sensitivity 
(89-93%) and specificity (81-92%), suggesting 
that the Xpert® MTB/RIF could be used as a 
diagnostic tool for ruling out TB or MDR-TB in 
Indonesia as one of the countries with a high TB 
burden.8 An effective TB treatment requires an 
accurate and early diagnosis as well as screening 
for drug resistance and HIV, which should be 
done with a low testing cost per sample.17 Thus, 
new TB cases can directly benefit from the use of 
this Xpert® MTB/RIF examination. 
Earlier diagnosis of pulmonary TB 
using Xpert MTB/RIF examination will lead 
to earlier and appropriate treatment. This 
examination can be used not only for sputum 
samples but also for urine and stool samples with high validity.18,19 Thus, it provides opportunities 
to prevent TB transmission by providing some 
hospitals with Xpert® MTB/RIF to reach remote 
areas with high TB prevalence and dense population, making this a highly recommended 
approach. The  Xpert® MTB/RIF examination 
Table 5 Distribution of Xpert® MTB/RIF and DST Results among MDR-TB Patients from 
 Dr. Hasan Sadikin General Hospital Bandung, Indonesia, 2012–2016 
MDR-TB (+)
DST
MDR-TB (-)
(n=339)
Total
(n=239) (n=578)
Xpert® MTB/RIF
MDR-TB (+) 300 79 379
MDR-TB (-) 39 160 199
Note: drug sensitivity test (DST )
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can serve as a new tool for rapid multi-drug resistance detection.20
The Xpert MTB/RIF examination is implemented to shorten the diagnosis time, 
which will enable early initiation of MDR-TB 
treatment. However, one should bear in mind 
that false positivity might be seen in Xpert MTB/
RIF examinations. Since the Xpert MTB/RIF 
examination is a molecular test, unviable bacilli in sputum that might arise during sputum decontamination or delay in transportation 
and inoculation can be detected as positive as 
described in previous study.8  
This study carries some limitations; not all patients have completed a standard test 
result in the database. Better integration of 
data management from different laboratories 
is highly needed, using a new technology in 
the digital era. Furthermore, as explained 
above, the Xpert MTB/RIF examination only 
detect rifampicin resistance while DST can 
detect other drug resistance also. Recently, 
several new molecular tests are introduced as diagnostic tools, including the line probe assay 
(LPA) that can detect more drug resistance 
such as isoniazid, rifampicin, fluoroquinolone, and any other second-line drug resistance. 
Further studies to compare the Xpert MTB/RIF 
examination with other molecular tests might 
be of great benefit as an effort to further explore 
drug resistance in a population. An accuracy 
of 79% is relatively high, considering that the 
Xpert MTB/RIF examination is a new tool at the time of the study. It is necessary to evaluate the 
Xpert MTB/RIF examination in a later period. In 
conclusion, Xpert® MTB/RIF examination has a 
satisfactory diagnostic performance for MDR-TB compared to culture as a gold standard due to its 
relatively high sensitivity and accuracy. Xpert® 
MTB/RIF examination is thus recommended 
for MDR-TB screening as a complement to the 
reference standard test, with confirmation 
using culture and DST. This could improve the 
affordability, rapidity, and precision of TB or 
MDR-TB detection for people in need, as well as adding to the data for further research.
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